$PFE key, this trial is.

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery - Full Text View - https://t.co/StN1dCjq7t https://t.co/G9XbNrWQMh